More MS news articles for April 2001

Marathoner on Pace to Beat MS
 
http://finance.individual.com/display_news.asp?doc_id=PR20010413CGF008&page=news

Friday April 13  9:02am
Source: PR Newswire

BOSTON, April 13 /PRNewswire/ -- While others ran against the clock and the crowd, Wendy Booker ran against a hidden competitor: multiple sclerosis (MS). She crossed the line of her first marathon in four hours and 46 minutes. She didn't break a race record, but she beat the perceptions associated with MS. On April 16, Wendy will lace up her sneakers to go after a personal record and to raise awareness for her personal fight.

True Grit

After finishing her first marathon, Wendy Booker was unsure if she would ever run 26.2 miles again. Her training partner and lifelong friend, Carol, had sworn off another marathon. Wendy feared the early morning training runs by herself and the grueling mental torture of race day. Instead she focused on what her running means in the bigger picture.

"This year I am focused on more than just finishing the race. I want everyone to know what people living with this disease can do. I want to be an inspiration for others living with MS," said Booker.

In 2000, Wendy teamed up with Carol, the National MS Society - Central New England Chapter "Marathon Strides Against MS" team, and Team COPAXONE(R) (glatiramer acetate for injection). Through her partnerships, friends, family, and various, generous donors, Wendy raised more than $8,000 for the NMSS and MS research. She hopes to duplicate her success and add to her fundraising total in 2001.

"I never would have run a marathon had I not been diagnosed with MS. To run successfully, you really have to want it. You need something deep from within to accomplish it," said Booker. "All the runners I know have their own agenda for taking on a marathon, mine was MS. This year, I want to run faster and raise more money while challenging the perceptions of what people living with MS can do. "

Racing the Disease

When Booker was diagnosed with relapsing-remitting multiple sclerosis (RRMS) in June 1998, she knew very little about the disease and its effects. Booker feared she would lose the ability to do the one thing she loved most -- run. To put her mind at ease, she learned all she could about the disease and its symptoms. She thought the more she learned, the better she would be mentally and physically. Now, Booker is helping others learn about her success. In 2000, she traveled across the country and spoke to others living with MS.

"After the race, I wanted people to know my story and see that they could still achieve personal goals, like a marathon, even though they have MS," said Booker. "I have had many people come up to me and say they were afraid of what life would be like after the diagnosis, but now they are planning the vacation they have always dreamed of or getting back into gardening, all sorts of things. I feel fortunate that I have been able to connect with others living with MS."

Booker talks to others about her experience with MS and directs audiences to resources like Shared Solutions(TM), the National Multiple Sclerosis Society, and MSWatch(R). Each one provided her with the answers she needed to come to terms with her diagnosis.

Advances in Medicine

Advances in medicine have led neurologists to treatments that can modify the immune processes thought to be responsible for relapsing-remitting multiple sclerosis. The FDA has approved drugs, such as COPAXONE(R) (glatiramer acetate for injection) that Booker takes. COPAXONE(R) helps reduce the frequency of relapses in people with relapsing-remitting multiple sclerosis. While individual results may vary, she has not suffered a relapse since 1998.

The most common side effects of COPAXONE(R) are redness, pain, swelling, itching, or a lump at the site of injection, flushing, chest pain, weakness, infection, pain, nausea, joint pain, anxiety, and muscle stiffness. These reactions are usually mild and seldom require professional treatment. Patients should tell their doctor about any side effects.

Some patients report a short-term reaction right after injecting COPAXONE(R) (glatiramer acetate for injection). This reaction can involve flushing (feeling of warmth and/or redness), chest tightness, or pain with heart palpitations, anxiety, and trouble breathing. These symptoms generally appear within minutes of an injection, last about 15 minutes, and go away by themselves without further problems.

Team COPAXONE(R)

Booker is a member of Team COPAXONE(R). She is just one example of someone who is living with relapsing-remitting multiple sclerosis and pursuing her dreams. Team COPAXONE(R) celebrates the accomplishments of people like Booker who refuse to let MS stand in their way. Members are working to change the perceptions that society holds of people living with multiple sclerosis. The days when people were sent home and told to go to bed and prepare for a wheelchair are at last disappearing. Today a combination of lifestyle changes, medical management, and will power are helping people like Booker to live out their dreams.

"Each mile that I run makes me feel empowered and proud of how I am managing my disease instead of letting it manage me," Booker stated. "The 26.2 miles in the Boston Marathon will help me demonstrate that those of us living with MS don't have to give up the things we love. For me, that is running."

Call 1-800-887-8100 for more information about COPAXONE(R) or multiple sclerosis. Teva Neuroscience LLC markets COPAXONE(R).

See additional important information at http://www.copaxone.com/pi/index.html or call 1-800-887-8100.

COPAXONE(R) is a registered trademark of Teva Pharmaceutical Industries, Ltd.

MSWatch(R) and Shared Solutions(TM) are trademarks of Teva Neuroscience LLC.

323203/8372C1

For product information, please call 1-800-753-0352 ext.738.

CONTACT: Jennifer Westphal of Fleishman-Hillard, 816-512-2241, westphaj@fleishman.com , for Teva Pharmaceutical Industries, Ltd.

Source: Teva Pharmaceutical Industries, Ltd.

Contact: Jennifer Westphal of Fleishman-Hillard, 816-512-2241, westphaj@fleishman.com , for Teva Pharmaceutical Industries, Ltd.